Heart failure (HF) is the leading cause of hospitalization in the elderly and occurs in the presence of preserved ejection fraction (EF) (diastolic HF, DHF) in over 50% of cases. DHF is rapidly increasing in prevalence. To date, no therapy is proven to improve symptoms or survival in DHF and thus, survival of patients with DHF has not improved over time. Based on our previous studies and on the tremendous unmet clinical need for an effective therapy for DHF, the broad objective this proposal is to develop a highly novel, cardiac specific and ultimately translatable therapy for DHF based on over-expressing natriuretic peptide receptors (guanylyl cyclase A (GCA)) in the heart. Our broad hypothesis is that augmenting cardiac GCA will ameliorate adverse remodeling and diastolic dysfunction in DHF. Our highly novel approach will utilize the markedly cardiotropic recombinant adeno-associated virus serotype 9 (AAV-9) vector to over-express GCA in the heart in our well established canine model of DHF. Our preliminary studies have established the rationale for over-expression of GCA as a therapy for DHF, established the ability to enhance GCA activity in the heart via AAV-9-GCA gene delivery in the rodent and established the feasibility of gene delivery in the canine. Our proposed Specific Aims outline the strategy to optimize overexpression of GCA in the canine heart via AAV-9 gene delivery, demonstrate that restoration of cardiac GCA in canine DHF abrogates adverse remodeling and diastolic dysfunction and determine the relative and incremental effect of AAV-9-GCA to phosphodiesterase type 5 inhibition. These studies lay the foundation for translation to human DHF in future studies if our hypothesis is proven correct.
SPECIFIC AIM 1 : Optimize AAV-9-cGCA gene delivery in the normal canine. Hypothesis: Optimized AAV-9- cGCAgene delivery results in increased cardiac GCA protein and activity.
SPECIFIC AIM 2 : Determine if AAV-9-cGCA increases GCA protein expression and activity and ameliorates adverse LV remodeling and diastolic dysfunction in canine DHF. Hypothesis: AAV-9-cGCA gene delivery results in increased GCA protein and activity, less hypertrophy and fibrosis and improved diastolic function in canine DHF.
SPECIFIC AIM 3 : Determine the relative and incremental effects of AAV-9-cGCA and PDE-5 inhibition in canine DHF. Hypothesis: Concomitant PDE-5 inhibition and AAV-9-cGCA provides incremental improvement in hypertrophy, fibrosis and diastolic function as compared to AAV-9-cGCA alone or PDE-5 inhibition alone in canine DHF.

Public Health Relevance

This proposal seeks to develop a novel, cardiac specific and ultimately translatable therapy for diastolic heart failure (DHF) based on the cardiac specific over-expression of the natriuretic peptide receptor (guanylyl cyclase A (GCA)) via adeno-associated viral (AAV) gene delivery in a canine model of DHF. We will optimize cardiac specific over expression of GCA in the normal canine, demonstrate that restoration of cardiac GCA via gene delivery ameliorates adverse LV remodeling and diastolic dysfunction in canine experimental DHF and determine the relative and incremental impact of AAV-9-GCA as compared to other therapeutic strategies. These studies lay the foundation for translation to human DHF in future studies.

Agency
National Institute of Health (NIH)
Type
Research Project (R01)
Project #
5R01HL105418-03
Application #
8700474
Study Section
Cardiac Contractility, Hypertrophy, and Failure Study Section (CCHF)
Program Officer
Evans, Frank
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Mohammed, Selma F; Majure, David T; Redfield, Margaret M (2016) Zooming in on the Microvasculature in Heart Failure With Preserved Ejection Fraction. Circ Heart Fail 9:
Zakeri, Rosita; Moulay, Gilles; Chai, Qiang et al. (2016) Left Atrial Remodeling and Atrioventricular Coupling in a Canine Model of Early Heart Failure With Preserved Ejection Fraction. Circ Heart Fail 9:
Degen, Chantal V; Bishu, Kalkidan; Zakeri, Rosita et al. (2015) The emperor's new clothes: PDE5 and the heart. PLoS One 10:e0118664
Moulay, Gilles; Ohtani, Tomohito; Ogut, Ozgur et al. (2015) Cardiac AAV9 Gene Delivery Strategies in Adult Canines: Assessment by Long-term Serial SPECT Imaging of Sodium Iodide Symporter Expression. Mol Ther 23:1211-21
Mohammed, Selma F; Hussain, Saad; Mirzoyev, Sultan A et al. (2015) Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation 131:550-9
Mohammed, Selma F; Redfield, Margaret M (2015) Response to Letters Regarding Article, "Coronary Microvascular Rarefaction and Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction". Circulation 132:e206
Borlaug, Barry A; Lewis, Gregory D; McNulty, Steven E et al. (2015) Effects of sildenafil on ventricular and vascular function in heart failure with preserved ejection fraction. Circ Heart Fail 8:533-41
AbouEzzeddine, Omar F; Haines, Phillip; Stevens, Susanna et al. (2015) Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure). JACC Heart Fail 3:245-52
Mohammed, Selma F; Borlaug, Barry A; McNulty, Steven et al. (2014) Resting ventricular-vascular function and exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study. Circ Heart Fail 7:580-9
Gladden, James D; Linke, Wolfgang A; Redfield, Margaret M (2014) Heart failure with preserved ejection fraction. Pflugers Arch 466:1037-53

Showing the most recent 10 out of 17 publications